Characterization and Hsp104-induced artificial clearance of familial ALS-related SOD1 aggregates.

[1]  J. Shorter,et al.  Operational Plasticity Enables Hsp104 to Disaggregate Diverse Amyloid and Nonamyloid Clients , 2012, Cell.

[2]  S. Tsuji,et al.  A novel monoclonal antibody reveals a conformational alteration shared by amyotrophic lateral sclerosis‐linked SOD1 mutants , 2012, Annals of neurology.

[3]  A. Gitler,et al.  Compartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity , 2012, Proceedings of the National Academy of Sciences.

[4]  A. Biter,et al.  Functional analysis of conserved cis- and trans-elements in the Hsp104 protein disaggregating machine. , 2012, Journal of structural biology.

[5]  Sungsu Kim,et al.  Ataxin-1 occupies the promoter region of E-cadherin in vivo and activates CtBP2-repressed promoter. , 2011, Biochimica et biophysica acta.

[6]  M. Tuite,et al.  Hsp70/Hsp90 co‐chaperones are required for efficient Hsp104‐mediated elimination of the yeast [PSI+] prion but not for prion propagation , 2009, Yeast.

[7]  Seongman Kang,et al.  Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: implications for the pathogenesis of amyotrophic lateral sclerosis , 2009, Experimental & Molecular Medicine.

[8]  E. Foran,et al.  Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. , 2009, Antioxidants & redox signaling.

[9]  F. Sanz,et al.  Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils. , 2008, Journal of molecular biology.

[10]  S. Lindquist,et al.  Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. , 2008, The Journal of clinical investigation.

[11]  C. Behl,et al.  Heterodimer formation of wild-type and amyotrophic lateral sclerosis-causing mutant Cu/Zn-superoxide dismutase induces toxicity independent of protein aggregation. , 2008, Human molecular genetics.

[12]  K. Talbot,et al.  Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS , 2008, Progress in Neurobiology.

[13]  Alberto Ferri,et al.  Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. , 2008, Antioxidants & redox signaling.

[14]  Y. Shyu,et al.  Visualization of AP-1–NF-κB ternary complexes in living cells by using a BiFC-based FRET , 2008, Proceedings of the National Academy of Sciences.

[15]  J. Shorter.  Hsp104: A Weapon to Combat Diverse Neurodegenerative Disorders , 2007, Neurosignals.

[16]  V. Meininger,et al.  Amyotrophic lateral sclerosis: all roads lead to Rome , 2007, Journal of neurochemistry.

[17]  S. Walter,et al.  Substrate Binding to the Molecular Chaperone Hsp104 and Its Regulation by Nucleotides* , 2005, Journal of Biological Chemistry.

[18]  D. Rubinsztein,et al.  Overexpression of yeast hsp104 reduces polyglutamine aggregation and prolongs survival of a transgenic mouse model of Huntington's disease. , 2005, Human molecular genetics.

[19]  R. Morimoto,et al.  Structural properties and neuronal toxicity of amyotrophic lateral sclerosis–associated Cu/Zn superoxide dismutase 1 aggregates , 2005, The Journal of cell biology.

[20]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[21]  M. Sowa,et al.  The ClpB/Hsp104 molecular chaperone-a protein disaggregating machine. , 2004, Journal of structural biology.

[22]  Mark A Rizzo,et al.  An improved cyan fluorescent protein variant useful for FRET , 2004, Nature Biotechnology.

[23]  Jimena Weibezahn,et al.  Characterization of a Trap Mutant of the AAA+ Chaperone ClpB* , 2003, Journal of Biological Chemistry.

[24]  Takeharu Nagai,et al.  Shift anticipated in DNA microarray market , 2002, Nature Biotechnology.

[25]  M. Tuite,et al.  The elimination of the yeast [PSI+] prion by guanidine hydrochloride is the result of Hsp104 inactivation , 2001, Molecular microbiology.

[26]  J. Shefner,et al.  Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy , 1999, Neurology.

[27]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.